Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Honig

Showing results (251-260 of 273) with videos related to

Pageof 28
Sort By:
Neurobiology of Disease|April 7, 2019
Heritability and genetic variance of dementia with Lewy bodiesRita Guerreiro, Valentina Escott-Price, Dena G Hernandez, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Aging|May 16, 2025
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degenerationRowan Saloner, Adam M Staffaroni, Eric B Dammer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 25, 2025
Sex differences in clinical phenotypes of behavioral variant frontotemporal dementiaXulin Liu, Sterre C M de Boer, Kasey Cortez, et al.
Annals of Neurology|January 29, 2026
Individualized Atrophy-Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed-Effects ModelingShubir Dutt, Dana Leichter, Yann Cobigo, et al.
Acta Neuropathologica|February 11, 2019
Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLDCyril Pottier, Yingxue Ren, Ralph B Perkerson, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Deciphering Distinct Genetic Risk Factors for FTLD-TDP Pathological Subtypes via Whole-Genome SequencingCyril Pottier, Fahri Küçükali, Matt Baker, et al.
The Lancet. Neurology|May 5, 2018
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association studyCyril Pottier, Xiaolai Zhou, Ralph B Perkerson, et al.
Pageof 28

Showing results (251-260 of 273) with videos related to

Sort By:
Pageof 28
Neurobiology of Disease|April 7, 2019
Heritability and genetic variance of dementia with Lewy bodiesRita Guerreiro, Valentina Escott-Price, Dena G Hernandez, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Aging|May 16, 2025
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degenerationRowan Saloner, Adam M Staffaroni, Eric B Dammer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 25, 2025
Sex differences in clinical phenotypes of behavioral variant frontotemporal dementiaXulin Liu, Sterre C M de Boer, Kasey Cortez, et al.
Annals of Neurology|January 29, 2026
Individualized Atrophy-Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed-Effects ModelingShubir Dutt, Dana Leichter, Yann Cobigo, et al.
Acta Neuropathologica|February 11, 2019
Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLDCyril Pottier, Yingxue Ren, Ralph B Perkerson, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Deciphering Distinct Genetic Risk Factors for FTLD-TDP Pathological Subtypes via Whole-Genome SequencingCyril Pottier, Fahri Küçükali, Matt Baker, et al.
The Lancet. Neurology|May 5, 2018
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association studyCyril Pottier, Xiaolai Zhou, Ralph B Perkerson, et al.
Pageof 28